LONDON, July 9, 2014 /PRNewswire/ --
The trading session on Tuesday, July 08, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,906.62, down 0.69% and the NASDAQ Composite closed at 4,391.46, down 1.35%. The S&P 500 finished the day 0.70% lower at 1,963.71. The losses were broad based as nine out of ten sectors finished on a negative note. The S&P 500 Health Care Sector Index finished the day at 709.36, down 0.92%, while the index has advanced 2.11% in the previous one month. Investor-Edge has initiated coverage on the following equities: Ohr Pharmaceutical Inc. (NASDAQ: OHRP), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Agenus Inc. (NASDAQ: AGEN) and PDL BioPharma Inc. (NASDAQ: PDLI). Free technical research on OHRP, SNTA, AGEN and PDLI can be downloaded upon signing up at:
http://www.investor-edge.com/4665-register
Shares in Ohr Pharmaceutical Inc. advanced 0.76% on Tuesday, closing the session at $7.97. A total of 0.34 million shares were traded, which was below its three months average volume of 0.67 million shares. The stock moved between $7.66 and $8.01 during the session. Shares in Ohr Pharmaceutical Inc. have declined 4.78% in the previous three trading sessions and 14.48% in the last one month. However, the company's shares are up 1.14% from the beginning of 2014. The company's stock is trading below its 50-day and 200-day moving averages. The stock's 50-day moving average of $8.81 is below its 200-day moving average of $9.93. Moreover, Ohr Pharmaceutical Inc.'s stock has a Relative Strength Index (RSI) of 43.48. Sign up today to read free research on OHRP at:
http://www.investor-edge.com/4665-OHRP-09Jul2014.pdf
On Tuesday, shares in Synta Pharmaceuticals Corp. fluctuated between $4.42 and $4.76 before ending Tuesday's session 4.01% lower at $4.55. The company's stock reported a trading volume of 2.95 million shares, which was above its three months average volume of 1.65 million shares. Synta Pharmaceuticals Corp.'s stock has advanced 9.11% in the previous three trading sessions and 9.38% in the last one month, while the stock has lost 13.17% on YTD basis. Shares in Synta Pharmaceuticals Corp. are trading above their 50-day moving average. The stock's 50-day moving average of $4.19 is below its 200-day moving average of $5.05. Additionally, the company's shares have an RSI of 69.82. Sign up today to read free research on SNTA at:
http://www.investor-edge.com/4665-SNTA-09Jul2014.pdf
Agenus Inc.'s stock recorded a trading volume of 1.36 million shares, above its three months average volume of 0.90 million shares. On Tuesday, the stock finished the day at $3.40, which was 6.08% lower its previous day's closing of $3.62, and registered an intraday range of $3.32 and $3.71. Over the last one month and on YTD basis, shares in Agenus Inc. have gained 6.58% and 28.79%, respectively. However, the stock has declined 10.53% in the previous three trading sessions. Shares in Agenus Inc. are trading above their 50-day and 200-day moving averages of $3.07 and $3.04, respectively. Furthermore, the company's stock has an RSI of 56.54. Sign up today to read free research on AGEN at:
http://www.investor-edge.com/4665-AGEN-09Jul2014.pdf
On Tuesday, shares in PDL BioPharma Inc. declined 1.16%, closing the day at $9.41. The stock recorded a trading volume of 2.86 million shares, which was above its three months average volume of 2.30 million shares. The company's stock oscillated between $9.35 and $9.56 during the session. Shares in PDL BioPharma Inc. have fallen by 3.88% in the previous three trading sessions and 1.36% in the last one month. However, the company's stock is up 11.49% since the start of this year. PDL BioPharma Inc.'s shares are trading above their 50-day and 200-day moving averages of $9.19 and $8.63, respectively. Moreover, the company's stock traded at a PE ratio of 5.14 and has an RSI of 49.14. Sign up today to read free research on PDLI at:
http://www.investor-edge.com/4665-PDLI-09Jul2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.Investor-Edge.com
SOURCE Investor-Edge
